Many individuals notice changes in appetite and portion control within the first few weeks, especially as doses are gradually increased
The anticipated off-patent status of GLP-1 drugs within the next decade will furthermore allow for cheaper generic versions, making these medications more affordable and accessible
The majority of these events were rated as mild to moderate in severity, and most resolved without requiring treatment discontinuation
Use of specific dietary patterns Several dietary practices and topics of public interest intersect with use of GLP-1s, including ketogenic diets, intermittent fasting, and ultra-processed foods
#Obesity #WeightLoss #GLP1 #Semaglutide #Orforglipron #FDAApproval #EliLilly #NovoNordisk #HealthcareInnovation #Foundayo To view or add a comment, sign in More Relevant Posts The landscape of metabolic health is undergoing a seismic shift
Oral GLP-1 agonists (e.g., Rybelsus) are available, though less common
